Luftvägs- och allergisjukdomar

Reviderad 2020-01-01. Större ändringar: Ny matris astma vuxna enligt GINA. Behandling med endast kortverkande beta-2-stimulerare (SABA vid astma) oavsett symptomnivå rekommenderas inte längre -behandling med ICS bör startas omedelbart efter diagnosen ställts. Nytt graderingssystem vid KOL enligt GOLD, baseras på symtom och ej FEV. Noskapin enda rekommenderade läkemedel vid hosta.

Referenser och länkar kapitel Luftvägssjukdomar

Barnes, P. J. Mechanisms in COPD. Chest (2003). doi:10.1378/chest.117.2_suppl.10s

Brill, S. E. & Wedzicha, J. A. Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 1241–1252 (2014).

Marwah, R. J. et al. A pharmacological and clinical comparison of prednisolone and betamethasone in rheumatoid arthritis. Eur. J. Clin. Pharmacol. (1982). doi:10.1007/BF00613613

Dennett, E. J. et al. Antibiotics for exacerbations of asthma. Cochrane Database Syst. Rev. (2018). doi:10.1002/14651858.cd002741.pub2

Stefan, M. S. et al. Association of Antibiotic Treatment with Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated with Systemic Corticosteroids. JAMA Intern. Med. (2019). doi:10.1001/jamainternmed.2018.5394

Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2019 Report. (Accessed on February 04, 2019). (2019).

Jordan, R. E. et al. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. Heal. Technol Assess 19, (2015).

Andrianopoulos, V. et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respir. Med. (2015). doi:10.1016/j.rmed.2015.06.013

Peters, M. Single-Inhaler Combination Therapy for Maintenance and Relief of Asthma. Drugs 69, 137–150 (2009).

Barnes, P. J. Scientific rationale for using a single inhaler for asthma control. Eur. Respir. J. 29, 587–595 (2007).

O’Byrne, P. M., Pedersen, S., Lamm, C. J., Tan, W. C. & Busse, W. W. Severe Exacerbations and Decline in Lung Function in Asthma. Am. J. Respir. Crit. Care Med. 179, 19–24 (2009).

Selroos, O., Pietinalho, A., Löfroos, A.-B. & Riska, H. Effect of Early vs Late Intervention With Inhaled Corticosteroids in Asthma. Chest 108, 1228–1234 (1995).

Selroos, O. Effect of disease duration on dose–response of inhaled budesonide in asthma. Respir. Med. 102, 1065–1072 (2008).

Global Initiative för Asthma. Global Strategy for Asthma Management and Prevention. (2019).

Brusselle, G. G. et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax 68, 322–329 (2013).

Gibson, P. G. et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 390, 659–668 (2017). För hänvisningsblankett se: Rökstopp remiss

Halbert, R. J. et al. Global burden of COPD: Systematic review and meta-analysis. European Respiratory Journal 28, 523–532 (2006).

Thorn, J. et al. Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: A real-life study and cost-effectiveness analysis. Prim. Care Respir. J. 21, 159–166 (2012).

Lopez, A. D. et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur. Respir. J. 27, 397–412 (2006).

Gillen, M. et al. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler. Pulm. Pharmacol. Ther. 52, 7–17 (2018).

Lundbäck, B., Backman, H. & Virchow, J. C. Inhaled corticosteroids and pneumonia risk - Revised knowledge. Respir. Med. 131, 247–248 (2017).

Rogliani, P. et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. Volume 13, 3115–3130 (2018).

Newman, S. P., Brown, J., Steed, K. P., Reader, S. J. & Kladders, H. Lung Deposition of Fenoterol and Flunisolide Delivered Using a Novel Device for Inhaled Medicines: Comparison of RESPIMAT With Conventional Metered-Dose Inhalers With and Without Spacer Devices. Chest 113, 957–963 (1998).

Eaton, L. Asthma drugs: industry and government look for greener methods of delivery. BMJ 365, (2019).

UpToDate - Pharmacotherapy of allergic rhinitis. (Accessed: 23rd September 2019)

Anafylaxi - Svenska Föreningen för Allergologi. (2015).



Hade du nytta av informationen?